Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology
Source abstract
Abstract
Abstract In recent decades, subcutaneous (SC) administration of monoclonal antibodies (mAbs) has emerged as a promising alternative to intravenous delivery in oncology, offering comparable therapeutic efficacy while addressing patient preferences. This perspective article provides an in‐depth analysis of the technological landscape surrounding SC mAb administration in oncology. It outlines various technologies under evaluation across developmental stages, spanning from preclinical investigations to the integration of established methodologies in clinical practice. Additionally, this perspective article explores emerging trends and prospective trajectories, shedding light on the evolving landscape of SC mAb administration. Furthermore, it emphasizes key checkpoints related to quality attributes essential for optimizing mAb delivery via the SC route. This review serves as a valuable resource for researchers, clinicians, and healthcare policymakers, offering insights into the advancement of SC mAb administration in oncology and its implications for patient care.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Microfluidic and Bio-sensing Technologies · Innovative Microfluidic and Catalytic Techniques Innovation · Microfluidic and Capillary Electrophoresis Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institut de Cancérologie Strasbourg Europe Strasbourg 67000 France
Equipe labellisée Ligue contre le Cancer, France
Strasbourg Drug Discovery and Development Institute (IMS) Strasbourg 67000 France
Equipe de Synthèse Pour l'Analyse Institut Pluridisciplinaire Hubert Curien (IPHC) UMR 7178 CNRS/University of Strasbourg Strasbourg Cedex 2 67087 France
Funding
HORIZON EUROPE European Research Council · H2020 European Research Council · Ligue Contre le Cancer
References (100+)
Show source-provided references
1. 10.1158/0008-5472.CAN-21-110910.1158/0008-5472.CAN-21-1109 ↗
2. 10.3390/antib903003410.3390/antib9030034 ↗
3. 10.1016/j.xphs.2021.11.00810.1016/j.xphs.2021.11.008 ↗
4. 10.1002/cpt.315010.1002/cpt.3150 ↗
5. 10.1007/s41669-022-00361-310.1007/s41669-022-00361-3 ↗
6. 10.1038/s41416-020-01255-z10.1038/s41416-020-01255-z ↗
7. 10.1007/s12325-019-01101-610.1007/s12325-019-01101-6 ↗
8. 10.1111/ecc.1325310.1111/ecc.13253 ↗
9. 10.1016/S1470-2045(13)70383-810.1016/S1470-2045(13)70383-8 ↗
10. 10.1002/cam4.57310.1002/cam4.573 ↗
11. 10.1016/j.jbi.2014.02.01710.1016/j.jbi.2014.02.017 ↗
12. 10.1371/journal.pone.015795710.1371/journal.pone.0157957 ↗
13. 10.1371/journal.pone.022796110.1371/journal.pone.0227961 ↗
14. 10.3390/ph1405045010.3390/ph14050450 ↗
15. 10.3390/ph709094310.3390/ph7090943 ↗
16. 10.3390/ph705053010.3390/ph7050530 ↗
17. 10.1377/hlthaff.2022.0144810.1377/hlthaff.2022.01448 ↗
18. 10.3390/biomedicines1008204510.3390/biomedicines10082045 ↗
19. 10.1016/j.semarthrit.2021.11.00910.1016/j.semarthrit.2021.11.009 ↗
20. Yousef H. · 2024
21. 10.1038/s41392-021-00544-010.1038/s41392-021-00544-0 ↗
22. Netti P. A. · Cancer Res. · 2000 · 60 · 2497
23. 10.1080/19420862.2020.177002810.1080/19420862.2020.1770028 ↗
24. 10.18433/jpps3002810.18433/jpps30028 ↗
25. 10.1016/j.xphs.2018.01.00710.1016/j.xphs.2018.01.007 ↗
26. 10.4161/mabs.4.1.1854310.4161/mabs.4.1.18543 ↗
27. 10.1038/s44222-024-00161-w10.1038/s44222-024-00161-w ↗
28. 10.1371/journal.pone.015789410.1371/journal.pone.0157894 ↗
29. 10.1016/j.matbio.2010.08.00110.1016/j.matbio.2010.08.001 ↗
30. 10.1007/s40259-020-00465-410.1007/s40259-020-00465-4 ↗
31. 10.1016/j.mvr.2021.10422810.1016/j.mvr.2021.104228 ↗
32. 10.1208/s12248-012-9367-010.1208/s12248-012-9367-0 ↗
33. 10.1016/j.jconrel.2006.05.02710.1016/j.jconrel.2006.05.027 ↗
34. Study Details | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non‐Small Cell Lung Cancer and Small Cell Lung Cancer | ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04870112?id=NCT04870112&rank=(accessed: March 2024).
35. 10.5187/jast.2021.e3410.5187/jast.2021.e34 ↗
36. 10.1016/j.curtheres.2020.10060410.1016/j.curtheres.2020.100604 ↗
37. 10.1080/10717544.2018.155144210.1080/10717544.2018.1551442 ↗
38. 10.1517/17425247.4.4.42710.1517/17425247.4.4.427 ↗
39. 10.1016/S1470-2045(12)70329-710.1016/S1470-2045(12)70329-7 ↗
40. 10.1093/annonc/mdu52410.1093/annonc/mdu524 ↗
41. 10.1093/annonc/mdu36410.1093/annonc/mdu364 ↗
42. 10.1016/j.ejca.2017.05.01010.1016/j.ejca.2017.05.010 ↗
43. 10.1007/s10549-021-06145-310.1007/s10549-021-06145-3 ↗
44. 10.1016/j.ejca.2017.08.01910.1016/j.ejca.2017.08.019 ↗
45. 10.1002/cpt.238510.1002/cpt.2385 ↗
46. 10.1208/s12248-012-9340-y10.1208/s12248-012-9340-y ↗
47. 10.1038/bjc.2013.37110.1038/bjc.2013.371 ↗
48. 10.1016/j.breast.2015.01.00210.1016/j.breast.2015.01.002 ↗
49. 10.1177/009127001243656010.1177/0091270012436560 ↗
50. 10.2217/fon-2019-016010.2217/fon-2019-0160 ↗
51. 10.1016/j.ejca.2017.04.02810.1016/j.ejca.2017.04.028 ↗
52. 10.1001/jamaoncol.2019.033910.1001/jamaoncol.2019.0339 ↗
53. 10.1016/S1470-2045(20)30536-210.1016/S1470-2045(20)30536-2 ↗
54. 10.1016/S2352-3026(20)30070-310.1016/S2352-3026(20)30070-3 ↗
55. 10.1016/S2352-3026(17)30078-910.1016/S2352-3026(17)30078-9 ↗
56. 10.1016/S1470-2045(14)70005-110.1016/S1470-2045(14)70005-1 ↗
57. 10.1093/annonc/mdw68510.1093/annonc/mdw685 ↗
58. 10.1002/cpdd.93610.1002/cpdd.936 ↗
59. 10.1016/j.jconrel.2019.10.04010.1016/j.jconrel.2019.10.040 ↗
60. 10.1001/jamaoncol.2019.083610.1001/jamaoncol.2019.0836 ↗
61. 10.1200/JCO.2018.36.15_suppl.e1564710.1200/JCO.2018.36.15_suppl.e15647 ↗
62. 10.1007/s11095-022-03294-y10.1007/s11095-022-03294-y ↗
63. 10.1002/jps.2219010.1002/jps.22190 ↗
64. 10.1016/j.jchromb.2017.09.03310.1016/j.jchromb.2017.09.033 ↗
65. 10.1016/j.csbj.2022.09.03510.1016/j.csbj.2022.09.035 ↗
66. 10.1021/acs.iecr.6b0204210.1021/acs.iecr.6b02042 ↗
67. 10.1007/s11095-018-2398-110.1007/s11095-018-2398-1 ↗
68. 10.1016/j.xphs.2019.03.00810.1016/j.xphs.2019.03.008 ↗
69. 10.1016/j.xphs.2019.06.00510.1016/j.xphs.2019.06.005 ↗
70. 10.1016/j.xphs.2017.06.01710.1016/j.xphs.2017.06.017 ↗
71. 10.1021/acs.molpharmaceut.5b0064310.1021/acs.molpharmaceut.5b00643 ↗
72. 10.1016/j.pep.2007.02.01010.1016/j.pep.2007.02.010 ↗
73. 10.1016/j.ijpharm.2024.12405510.1016/j.ijpharm.2024.124055 ↗
74. 10.1016/j.ijpharm.2022.12220410.1016/j.ijpharm.2022.122204 ↗
75. 10.1007/s11095-016-2055-510.1007/s11095-016-2055-5 ↗
76. 10.1002/jps.2345310.1002/jps.23453 ↗
77. 10.1016/j.molliq.2022.12034910.1016/j.molliq.2022.120349 ↗
78. 10.1016/j.xphs.2020.12.01610.1016/j.xphs.2020.12.016 ↗
79. 10.1038/s41551-021-00698-w10.1038/s41551-021-00698-w ↗
80. 10.1016/j.addr.2021.02.00210.1016/j.addr.2021.02.002 ↗
81. 10.1016/j.biomaterials.2014.08.00110.1016/j.biomaterials.2014.08.001 ↗
82. 10.1021/ma100093b10.1021/ma100093b ↗
83. 10.1039/C7CS00391A10.1039/C7CS00391A ↗
84. 10.1002/btm2.1003110.1002/btm2.10031 ↗
85. 10.3390/pharmaceutics1212118810.3390/pharmaceutics12121188 ↗
86. 10.1146/annurev.bioeng.2.1.910.1146/annurev.bioeng.2.1.9 ↗
87. 10.3390/ijms2307366510.3390/ijms23073665 ↗
88. 10.1002/app.3165410.1002/app.31654 ↗
89. 10.1016/j.ijpharm.2008.08.02710.1016/j.ijpharm.2008.08.027 ↗
90. 10.1016/j.msec.2015.10.09610.1016/j.msec.2015.10.096 ↗
91. 10.1021/acs.nanolett.8b0140610.1021/acs.nanolett.8b01406 ↗
92. 10.3390/nano1102047110.3390/nano11020471 ↗
93. 10.1002/adma.20230873810.1002/adma.202308738 ↗
94. 10.1016/j.mtchem.2022.10122210.1016/j.mtchem.2022.101222 ↗
95. 10.1016/j.polymdegradstab.2020.10930810.1016/j.polymdegradstab.2020.109308 ↗
96. 10.1016/j.actbio.2021.04.00910.1016/j.actbio.2021.04.009 ↗
97. 10.1016/j.actbio.2019.01.00310.1016/j.actbio.2019.01.003 ↗
98. 10.1038/s41467-022-29121-x10.1038/s41467-022-29121-x ↗
99. 10.1016/j.biomaterials.2021.12116610.1016/j.biomaterials.2021.121166 ↗
100. 10.3390/ijms23231461110.3390/ijms232314611 ↗